Cell & Gene Therapy Manufacturing Services Market by Type, Indication, Application, End-User

Description

List of Tables

[185 Pages Report] The Cell & Gene Therapy Manufacturing Services Market size was estimated at USD 17.34 billion in 2023 and expected to reach USD 19.98 billion in 2024, at a CAGR 15.81% to reach USD 48.45 billion by 2030.

Global Cell & Gene Therapy Manufacturing Services Market

KEY MARKET STATISTICS
Base Year [2023]	USD 17.34 billion
Estimated Year [2024]	USD 19.98 billion
Forecast Year [2030]	USD 48.45 billion
CAGR (%)	15.81%

Cell & Gene Therapy Manufacturing Services Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cell & Gene Therapy Manufacturing Services Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cell & Gene Therapy Manufacturing Services Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Manufacturing Services Market, highlighting leading vendors and their innovative profiles. These include Bluebird Bio, Inc., Boehringer Ingelheim International GmbH, c-LEcta GmbH, Catalent, Inc., Cell and Gene Therapy Catapult, Cell Therapies Pty Ltd., Charles River Laboratories International, Inc., F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Innovative Cellular Therapeutics Co., Ltd., Lonza Group, Merck KGaA, Miltenyi Biotec B.V. & Co. KG, Nikon Corporation, Novartis AG, Oxford Biomedica PLC, Samsung Biologics Co., Ltd, Showa Denko K.K., Takara Bio Inc., Thermo Fisher Scientific, Inc., and Wuxi Apptec Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Manufacturing Services Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
- Cell Therapy
  - Allogeneic
    - Allogeneic Hematopoietic Stem Cells
    - Allogeneic Induced Pluripotent Stem Cells
    - Allogeneic Mesenchymal Stem Cells
    - Allogeneic Natural Killer Cells
    - Allogeneic T-cells
  - Autologous
    - Autologous Hematopoietic Stem Cells
    - Autologous Mesenchymal Stem Cells
    - Autologous Natural Killer Cells
    - Autologous T-cells
  - Viral Vector
    - Adeno-associated Virus Vectors
    - Retroviral Vectors
- Gene Therapy
  - Non-viral Vector
  - Oligonucleotides
Indication
- Cardiovascular Diseases
- Central Nervous System Disorders
- Infectious Diseases
- Oncology Diseases
- Ophthalmology Diseases
- Orthopedic Diseases
Application
- Clinical Manufacturing
- Commercial Manufacturing
End-User
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cell & Gene Therapy Manufacturing Services Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cell & Gene Therapy Manufacturing Services Market?

3. What are the technology trends and regulatory frameworks in the Cell & Gene Therapy Manufacturing Services Market?

4. What is the market share of the leading vendors in the Cell & Gene Therapy Manufacturing Services Market?

5. Which modes and strategic moves are suitable for entering the Cell & Gene Therapy Manufacturing Services Market?

Product Code: MRR-BB6269D14168

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Cell & Gene Therapy Manufacturing Services Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. High Incidence of Cancer and Other Target Diseases
  - 5.1.1.2. Increasing Investments in Pharmaceutical R&D and Advanced Technologies by CDMOs
  - 5.1.1.3. Focus on the Personalized Medicine with the Rising Tendency Towards Early Disease Diagnosis
- 5.1.2. Restraints
  - 5.1.2.1. High Operational Costs Associated With Cell & Gene Therapy Manufacturing Services
- 5.1.3. Opportunities
  - 5.1.3.1. Emergence of Advanced Analytical Technologies in Development of Cell & Gene Therapy
  - 5.1.3.2. Improvement in the Supply Chain of Cell & Gene Therapy Manufacturing
- 5.1.4. Challenges
  - 5.1.4.1. Quality Control and Contamination Issues in Cell & Gene Therapy Production
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Cell & Gene Therapy Manufacturing Services Market, by Type

6.1. Introduction
6.2. Cell Therapy
- 6.3.1. Allogeneic
  - 6.3.2.1. Allogeneic Hematopoietic Stem Cells
  - 6.3.2.2. Allogeneic Induced Pluripotent Stem Cells
  - 6.3.2.3. Allogeneic Mesenchymal Stem Cells
  - 6.3.2.4. Allogeneic Natural Killer Cells
  - 6.3.2.5. Allogeneic T-cells
- 6.3.2. Autologous
  - 6.3.3.1. Autologous Hematopoietic Stem Cells
  - 6.3.3.2. Autologous Mesenchymal Stem Cells
  - 6.3.3.3. Autologous Natural Killer Cells
  - 6.3.3.4. Autologous T-cells
- 6.3.3. Viral Vector
  - 6.3.4.1. Adeno-associated Virus Vectors
  - 6.3.4.2. Retroviral Vectors
6.3. Gene Therapy
- 6.4.1. Non-viral Vector
- 6.4.2. Oligonucleotides

7. Cell & Gene Therapy Manufacturing Services Market, by Indication

7.1. Introduction
7.2. Cardiovascular Diseases
7.3. Central Nervous System Disorders
7.4. Infectious Diseases
7.5. Oncology Diseases
7.6. Ophthalmology Diseases
7.7. Orthopedic Diseases

8. Cell & Gene Therapy Manufacturing Services Market, by Application

8.1. Introduction
8.2. Clinical Manufacturing
8.3. Commercial Manufacturing

9. Cell & Gene Therapy Manufacturing Services Market, by End-User

9.1. Introduction
9.2. Academic & Research Institutes
9.3. Pharmaceutical & Biotechnology Companies

10. Americas Cell & Gene Therapy Manufacturing Services Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Cell & Gene Therapy Manufacturing Services Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Manufacturing Services Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
- 14.1.1. Bluebird Bio, Inc.
- 14.1.2. Boehringer Ingelheim International GmbH
- 14.1.3. c-LEcta GmbH
- 14.1.4. Catalent, Inc.
- 14.1.5. Cell and Gene Therapy Catapult
- 14.1.6. Cell Therapies Pty Ltd.
- 14.1.7. Charles River Laboratories International, Inc.
- 14.1.8. F. Hoffmann-La Roche Ltd.
- 14.1.9. FUJIFILM Holdings Corporation
- 14.1.10. Innovative Cellular Therapeutics Co., Ltd.
- 14.1.11. Lonza Group
- 14.1.12. Merck KGaA
- 14.1.13. Miltenyi Biotec B.V. & Co. KG
- 14.1.14. Nikon Corporation
- 14.1.15. Novartis AG
- 14.1.16. Oxford Biomedica PLC
- 14.1.17. Samsung Biologics Co., Ltd
- 14.1.18. Showa Denko K.K.
- 14.1.19. Takara Bio Inc.
- 14.1.20. Thermo Fisher Scientific, Inc.
- 14.1.21. Wuxi Apptec Co., Ltd.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing